Severe Clostridioides difficile Infection in the Intensive Care Unit-Medical and Surgical Management.

Autor:	Rimawi RH; Department of Medicine, Division of Pulmonary, Sleep, Allergy, and Critical Care Medicine, Emory University School of Medicine, 550 Peachtree Street NorthWest, Atlanta, GA 30308, USA. Electronic address: RamzyRimawi@emory.edu., Busby S; Department of Surgery, Emory University School of Medicine., Greene WR; Emory University, Emory University Hospital, American College of Surgeons Board of Governors, SESC DEI Committee, ECCC IDEA Committee, Surgical Section of the NMA and Surgical Leaders Foundation, Emory School of Medicine African American Women's Collaborative.
Jazyk:	angličtina
Zdroj:	Infectious disease clinics of North America [Infect Dis Clin North Am] 2022 Dec; Vol. 36 (4), pp. 889-895.
DOI:	10.1016/j.idc.2022.07.006
Abstrakt:	Clostridioides difficile remains a major cause of morbidity and mortality in the intensive care unit, and therefore, C difficile guidelines are frequently being updated. Currently, fidaxomicin is the suggested treatment of initial and recurrent infection. Oral vancomycin is an acceptable alternative, followed by rifaximin and fecal microbiota transplantation. Bezlotoxumab is suggested in recurrent cases within 6 months. If patients fail to improve within 3 to 5 days of therapy, especially in patients who have had nasogastric tubes or emergent surgery, fulminant colitis is possible and surgical consultation should be considered for total colectomy. (Copyright © 2022 Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu